Thomas Beck

4.8k total citations · 1 hit paper
56 papers, 3.5k citations indexed

About

Thomas Beck is a scholar working on Surgery, Oncology and Molecular Biology. According to data from OpenAlex, Thomas Beck has authored 56 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Surgery, 17 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Thomas Beck's work include Nausea and vomiting management (10 papers), Pregnancy and preeclampsia studies (7 papers) and HER2/EGFR in Cancer Research (7 papers). Thomas Beck is often cited by papers focused on Nausea and vomiting management (10 papers), Pregnancy and preeclampsia studies (7 papers) and HER2/EGFR in Cancer Research (7 papers). Thomas Beck collaborates with scholars based in Germany, United States and Switzerland. Thomas Beck's co-authors include John D. Crissman, James E. Montie, Michael F. Sarosdy, James E. Gottesman, Brent A. Blumenstein, Joseph T. Leimert, Bruce A. Lowe, Donald L. Lamm, E. David Crawford and H. Barton Grossman and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Clinical Oncology and Annals of Internal Medicine.

In The Last Decade

Thomas Beck

54 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A RANDOMIZED SOUTHWEST ONCOLOGY GROUP STUDY

2000 891 citations Thomas Beck et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Beck Germany	27	1.7k	1.0k	608	473	447	56	3.5k
Luigi Selvaggi Italy	39	879 0.5×	438 0.4×	388 0.6×	163 0.3×	436 1.0×	221	5.5k
Ashish Jain India	28	889 0.5×	349 0.3×	182 0.3×	541 1.1×	774 1.7×	139	3.6k
Jesper Reibel Denmark	32	798 0.5×	443 0.4×	334 0.5×	199 0.4×	608 1.4×	103	4.1k
Jae Wook Kim South Korea	31	834 0.5×	446 0.4×	342 0.6×	719 1.5×	951 2.1×	129	2.9k
Harald Rosén Austria	34	2.2k 1.3×	1.6k 1.5×	418 0.7×	177 0.4×	219 0.5×	98	4.1k
Elizabeth A. Beierle United States	31	797 0.5×	774 0.8×	510 0.8×	398 0.8×	1.1k 2.4×	187	3.2k
Derek G. Power Ireland	31	767 0.5×	1.2k 1.2×	655 1.1×	252 0.5×	568 1.3×	138	3.2k
Leonardo Resta Italy	32	544 0.3×	610 0.6×	433 0.7×	267 0.6×	684 1.5×	221	4.5k
Scott A. Strong United States	33	2.4k 1.4×	1.4k 1.3×	496 0.8×	161 0.3×	539 1.2×	87	5.6k
L E Hughes United Kingdom	38	1.7k 1.0×	1.1k 1.1×	368 0.6×	604 1.3×	653 1.5×	120	4.2k

Countries citing papers authored by Thomas Beck

Since Specialization

Citations

This map shows the geographic impact of Thomas Beck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Beck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Beck more than expected).

Fields of papers citing papers by Thomas Beck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Beck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Beck. The network helps show where Thomas Beck may publish in the future.

Co-authorship network of co-authors of Thomas Beck

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Beck. A scholar is included among the top collaborators of Thomas Beck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Beck. Thomas Beck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hölzel, D., Renate Eckel, Ingo Bauerfeind, et al.. (2016). Survival of de novo stage IV breast cancer patients over three decades. Journal of Cancer Research and Clinical Oncology. 143(3). 509–519. 30 indexed citations

Beck, Thomas, Helmut Rasch, Elisabeth Bruder, Rolf Hügli, & Christoph Kettelhack. (2009). Myositis Ossificans Presenting as a Tumor of the Cervical Paraspinal Muscles. European Journal of Trauma and Emergency Surgery. 36(3). 257–259. 2 indexed citations

Hermelink, Kerstin, Michael Untch, Michael P. Lux, et al.. (2007). Cognitive function during neoadjuvant chemotherapy for breast cancer. Cancer. 109(9). 1905–1913. 277 indexed citations

Oken, Martin M., Pamela M. Marcus, Ping Hu, et al.. (2005). Baseline Chest Radiograph for Lung Cancer Detection in the Randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. JNCI Journal of the National Cancer Institute. 97(24). 1832–1839. 95 indexed citations

Glick, John H., Mary Lynn Young, David Harrington, et al.. (1998). MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial.. Journal of Clinical Oncology. 16(1). 19–26. 77 indexed citations

Wilson, David B., et al.. (1997). Paclitaxel Formulation as a Cause of Ethanol Intoxication. Annals of Pharmacotherapy. 31(7-8). 873–875. 13 indexed citations

Beck, Thomas, A. Y. Chang, Rudolph M. Navari, et al.. (1997). Oral Ondansetron 8 mg Twice Daily is as Effective as 8 mg Three Times Daily in the Prevention of Nausea and Vomiting Associated with Moderately Emetogenic Cancer Chemotherapy. Cancer Investigation. 15(4). 297–303. 16 indexed citations

Navari, Rudolph M., Stefan Madajewicz, N. Anderson, et al.. (1995). Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo.. Journal of Clinical Oncology. 13(9). 2408–2416. 68 indexed citations

Beck, Thomas, et al.. (1995). Usefulness of Immunohistochemical Staining for p53 in the Prognosis of Breast Carcinomas: Correlations with Established Prognosis Parameters and with the Proliferation Marker, MIB-1. Gynecologic Oncology. 57(1). 96–104. 39 indexed citations

10.

Beck, Thomas, et al.. (1994). Immunohistochemical Detection of Hormone Receptors in Breast Carcinomas (ER-ICA, PgR-ICA): Prognostic Usefulness and Comparison with the Biochemical Radioactive-Ligand-Binding Assay (DCC). Gynecologic Oncology. 53(2). 220–227. 36 indexed citations

11.

Beck, Thomas, Franz Bahlmann, & Volker Möbus. (1994). Histometric investigations of placental villi in cases of unexpected fetal acidosis. Journal of Perinatal Medicine. 22(4). 309–317. 2 indexed citations

12.

Hesketh, Paul J., W. Henwood Harvey, W G Harker, et al.. (1994). A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis.. Journal of Clinical Oncology. 12(3). 596–600. 115 indexed citations

13.

Beck, Thomas, Franz Bahlmann, & W. Weikel. (1993). [Histology of chorioamnionitis: relations to maternal and fetal infection parameters].. PubMed. 197(3). 129–34. 3 indexed citations

14.

Hitschold, T, et al.. (1993). Low target birth weight or growth retardation? Umbilical Doppler flow velocity waveforms and histometric analysis of fetoplacental vascular tree. American Journal of Obstetrics and Gynecology. 168(4). 1260–1264. 64 indexed citations

15.

Beck, Thomas, Paul J. Hesketh, Stefan Madajewicz, et al.. (1992). Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting.. Journal of Clinical Oncology. 10(12). 1969–1975. 77 indexed citations

16.

Tanner, Berno, et al.. (1992). C-erbB-2-oncogene expression in breast carcinoma: Analysis by S1 nuclease protection assay and immunohistochemistry in relation to clinical parameters. Gynecologic Oncology. 47(2). 228–233. 10 indexed citations

17.

Möbus, Volker, C D Gerharz, R. Moll, et al.. (1992). Morphological, immunohistochemical and biochemical characterization of 6 newly established human ovarian carcinoma cell lines. International Journal of Cancer. 52(1). 76–84. 76 indexed citations

18.

Beck, Thomas. (1991). Placental morphometry using a computer assisted measuring programme: reference values for normal pregnancies at term. Archives of Gynecology and Obstetrics. 249(3). 135–147. 6 indexed citations

19.

Goodman, Gary E., John J. Crowley, John C. Blasko, et al.. (1990). Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.. Journal of Clinical Oncology. 8(1). 39–47. 48 indexed citations

20.

Beck, Thomas, G. Schweikhart, & E Stolz. (1986). Immunohistochemical location of HPL, SP1 and β-HCG in normal placentas of varying gestational age. Archives of Gynecology and Obstetrics. 239(2). 63–74. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact